Sept 19 (Reuters) - ProMIS Neurosciences Inc PMN.TO
* ProMIS Neurosciences announces successful humanization of lead product candidate PMN310 for alzheimer's disease
* ProMIS Neurosciences Inc - clinical trials evaluating PMN310 expected to initiate in 2019